WERBUNG
Kurse
Name | Kurs | Vortag | +/- % | +/- abs. | Zeit |
---|---|---|---|---|---|
Lang & Schwarz | 48.590 € | 49.510 € | -1.86 | -0.920 | 10:24:17 |
Tradegate | 55.400 € | 46.890 € | 18.15 | 8.510 | 24.06.2022 |
Stuttgart | 48.740 € | 49.550 € | -1.63 | -0.810 | 10:24:15 |
Baader Bank | 48.560 € | 49.910 € | -2.70 | -1.350 | 10:00:43 |
LS Exchange | 48.590 € | 49.510 € | -1.86 | -0.920 | 10:24:17 |
Quotrix | 48.590 € | 50.020 € | -2.86 | -1.430 | 10:24:11 |
gettex | 49.990 € | 49.990 € | 0.00 | 0.000 | 09:43:01 |
Lang & Schwarz weekend | 48.590 € | 49.510 € | -1.86 | -0.920 | 10:24:17 |
Nasdaq | 52.210 $ | 53.460 $ | -2.34 | -1.250 | 29.06.2022 |
Cboe BZX | 52.250 $ | 53.470 $ | -2.28 | -1.220 | 29.06.2022 |
Frankfurt | 48.800 € | 49.920 € | -2.24 | -1.120 | 08:11:16 |
Düsseldorf | 48.450 € | 50.220 € | -3.52 | -1.770 | 08:31:51 |
Berlin | 48.690 € | 49.940 € | -2.50 | -1.250 | 08:01:11 |
Chartanalysen zur Blueprint Medicines Corp. Aktie
- 18.12.2020 - BLUEPRINT MEDICINES - Bei dieser Biotech-Aktie lacht das Analystenherz von Bastian Galuschka
- 09.09.2019 - HotStocks USA: +76% bei ACADIA PHARMA, +54% bei CHANGYOU.COM von Bastian Galuschka
- 13.08.2019 - HotStocks USA: +126% bei DECIPHERA PHARMA, JD.COM stark gehandelt von Bastian Galuschka
- 05.06.2018 - ASCO-Nachlese: LOXO ONCOLOGY vs. BLUEPRINT MEDICINES von Bastian Galuschka
- 16.04.2018 - HotStocks USA: +16% bei ALKERMES, NETFLIX stark gehandelt von Bastian Galuschka
Analysten-Ratings zur Blueprint Medicines Corp. Aktie
WERBUNG
Schnellsuche von 
auf
WERBUNG
Die Blueprint Medicines Corp. Aktie auf einen Blick
Wichtigste Eigenschaften
- WKN
- ISIN
- Ticker DE2L9
- Ticker USBPMC
- AnlageklasseAktie
- LandUSA
- BrancheGesundheitswesen
- US-ListingNasdaq
- Index-ZugehörigkeitNasdaq Composite, NASDAQ Biotechnology Index
- Anzahl Aktien59,570,547.00
- Marktkapitalisierung3,184,641,442.00 $
Wertentwicklung
- Zeitraum%
- Intraday-1.86
- 1 Jahr-33.801
Mehr zur Blueprint Medicines Corp. Aktie
Beschreibung der Blueprint Medicines Corp. Aktie
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Passender Service
Guidants PROmax
ab 74.99 € mtl.
inkl. MwSt.
WERBUNG
Pivot Punkte zur Blueprint Medicines Corp. Aktie
Name | Wert |
---|---|
Pivot-HBOP — R3 | 52.600 € |
Pivot-Resist — R2 | 51.590 € |
Pivot-High — R1 | 50.550 € |
Pivotpunkt | 49.540 € |
Pivot-Low — S1 | 48.500 € |
Pivot-Support — S2 | 47.490 € |
Pivot-LBOP — S3 | 46.450 € |
Kurse & Charts
Weitere Publikationen
Services
Premium
Einsteiger & Wissen